FORM PTO-1390 (Modified)
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
(REV 12-2004)

	TRA	NSMITTAL LETTER TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER					
		ESIGNATED/ELECTED OFFICE (DO/EO/US)	033873-0108					
	CC	DNCERNING A FILING UNDER 35 U.S.C. 371	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/562,202					
INT	ERNATIO		PRIORITY DATE CLAIMED					
	PCT/JP04	······································	6/27/2003					
	ITLE OF INVENTION INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR CRANIAL NERVE DISEASES COMPRISING MESENCHYMAL CELLS AS AN ACTIVE INGREDIENT (As Amended)							
API	LICANT(S) FOR DO/EO/US						
Apr	Osamu HONMOU et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:							
1.		This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
2.	\boxtimes	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3.	\boxtimes	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4.	\boxtimes	The US has been elected (Article 31).						
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371(c)(2))						
		is attached hereto (required only if not communicated by the International Communicated	ational Bureau).					
			•					
		is not required, as the application was filed in the United States Rec	ceiving Office (RO/US)					
6.		An English language translation of the International Application as filed (35 ☐ is attached hereto. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).	5 U.S.C. 371(c)(2)).					
7.		Amendments to the claims of the International Application under PCT Articlar are attached hereto (required only if not transmitted by the International have been communicated by the International Bureau. have not been made; however, the time limit for making such amendment have not been made and will not be made.	ional Bureau).					
8.		An English language translation of the amendments to the claims under P	CT Article 19 (35 U.S.C. 371(c)(3)).					
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10.		An English language translation of the annexes to the International Prelimi 36 (35 U.S.C. 371(c)(5)).	inary Examination Report under PCT Article					
lter	ns 11 to 2	0 below concern other document(s) or information included:						
11.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12.		An assignment document for recording. A separate cover sheet in compliance	ance with 37 CFR 3.28 and 3.31 is included.					
13.		A preliminary amendment.						
14.		An Application Data Sheet under 37 CFR 1.76.						
15.		A substitute specification.						
16.		A power of attorney and/or change of address letter.						
17.	\boxtimes	A computer-readable form of the sequence listing in accordance with PCT	Rule 13ter.2 and 37 CFR 1.821 – 1.825					
18.		A second copy of the published international application under 35 U.S.C. 1	54(d)(4).					
19.		A second copy of the English language translation of the international appli	cation under 35 U.S.C. 154(d)(4).					
20.	\boxtimes	Other items or information: Return copy of Notice to Comply;						
		Statement to Support Filing and Submission in Accordance with 37 C.F.	.R. §§ 1.821-1.825					

1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -						Y'S DOCKET NUMBER 73-0108				
-	The following fees have been submitted:									
21. 🛛 Basic national fee \$300							\$	300.00		
22. Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) All other situations \$200							\$	200.00		
23.	Search fo	ee			_				<u> </u>	
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the										
USPTO as an International Searching Authority \$100										
International Search Report prepared and provided to the Office \$400										
All other situations \$500								\$	400.00	<u> </u>
_				22 and 23 =				\$	900.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.										
Total Shee	ets Extra	sheets		er of each additional 50 or t f (round up to a whole num		RAT	ΓE			
124 - 10		/50 =	L	1			250.00	\$	250.00	
earliest cla	imed priori	ty date (37 C	FR 1.49	1				\$	130.00	
CLA	IMS	NUMBER	_	NUMBER EXTRA		RATE		\$		
Total C	Claims	13	- 20 =	0	x \$		50.00	\$	0.00	
Independe		3	- 3 =	0	x \$		200.00	\$	0.00	
MULTIPLE	DEPEND	ENT CLAIM	(S) (if ap	<u> </u>	+ \$		360.00	\$		
		- 181		TOTAL OF ABOV			ONS =	\$	1280.00	
	plicant claiduced by 1/2		tity statu:	s. See 37 CFR 1.27. Fees	above are	Э	+	\$	0.00	
SUBTOTAL =							\$	1280.00		
Processing fee of 130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).										
TOTAL NATIONAL FEE =						\$	1280.00			
				TOTAL FEES	PREVIOU	SLY F	PAID =	\$	1280.00	
								Amount to be refunded:		
									charged:	
a. 🗌	A check i	n the amou	ınt of	to cover the above fe	es is enc	losed	d.			
b. Please charge my Deposit Account No. 19-0741 in the amount of to cover the above fees. A duplicate copy of this sheet is enclosed.										
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0741. A duplicate copy of this sheet is enclosed.										
d. Eees are to be charge to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-										
2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.										
SEND ALL CORRESPONDENCE TO:						Ept Blad				
SIGNATU						JRE				
						B. Maebius				
	Customer Number: 22428 NAME					AME				
35,264						 .				
						RE	EGISTE	RATIO	ON NUMBER	

JUL 1 4 2006



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO.

10/562,202 Osamu Honmou 033873-0108

INTERNATIONAL APPLICATION NO.

PCT/JP04/09386

22428 FOLEY AND LARDNER LLP SUITE 500 3000 K STREET NW WASHINGTON, DC 20007 PCT/JP04/09386

I.A. FILING DATE PRIORITY DATE

06/25/2004

CONFIRMATION NO. 4131 371 FORMALITIES LETTER

OC00000019511980

Date Mailed: 07/07/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules !aterpretation, call (571) 272-0951
- For Petentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

LAMONT M HUNTER

Telephone: (703) 308-9140 EXT 201

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.		
10/562,202	PCT/JP04/09386	033873-0108		

FORM PCT/DO/EO/922 (371 Formalities Notice)